Dizal Pharmaceuticals initiates trial for DZD8586 in relapsed B-cell Non-Hodgkin Lymphoma
Dizal Pharmaceuticals is conducting a study on DZD8586 for patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma.
Asset / Drug
Drug and asset intelligence for DZD8586 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.